PAPAVER BRACTEATUM WITH MODIFIED ALKALOID CONTENT
    6.
    发明申请
    PAPAVER BRACTEATUM WITH MODIFIED ALKALOID CONTENT 审中-公开
    具有改性的碱性内含物的PAPAVER BRACTEATUM

    公开(公告)号:WO2012058714A1

    公开(公告)日:2012-05-10

    申请号:PCT/AU2011/001400

    申请日:2011-10-31

    Abstract: The present invention relates to genetically modified plants of the species Papaver bracteatum wherein the type or amount of one or more alkaloids produced by the plants has been modified. Specifically, the genetically modified plants have an increased expression of one or more of thebaine 6-O-demethylase, codeine O- demethylase and/or codeinone reductase relative to wild type P. bracteatum such that the genetically modified poppy plants produce an increased quantity of an alkaloid selected from codeine, oripavine and/or morphine relative to a wild type P. bracteatum. Also provided are progeny plants having the genetically modified poppy plants described above as a parent; mutant or derivative plants of the aforementioned plants; reproductive material derived from, straw produced from, straw concentrate produced from, latex derived from, or one or more isolated cells derived from, the aforementioned plants. Methods for producing an alkaloid from the aforementioned plants are also provided, together with nucleic acid and amino acid sequence variants of the 6-O-demethylase and codeine O-demethylase genes.

    Abstract translation: 本发明涉及种植罂粟种的遗传修饰植物,其中由植物产生的一种或多种生物碱的类型或数量已被修饰。 具体而言,遗传修饰的植物相对于野生型P.actactactum具有增加的一种或多种蒂巴因6-O-脱甲基酶,可待因O-脱甲基酶和/或依尼可酮还原酶的表达,使得转基因罂粟植物产生增加量的 相对于野生型P.bracteatum,选自可待因,oripavine和/或吗啡的生物碱。 还提供了具有上述转基因罂粟植物作为亲本的后代植物; 上述植物的突变体或衍生植物; 衍生自生殖材料的生殖材料,由生产的秸秆浓缩物产生的秸秆,衍生自上述植物的胶原衍生自或一种或多种分离的细胞。 还提供了从上述植物生产生物碱的方法以及6-O-脱甲基酶和可待因O-去甲基化酶基因的核酸和氨基酸序列变体。

    PROCESS FOR PREPARING HYDROCODONE USING A SUPER ACID
    7.
    发明申请
    PROCESS FOR PREPARING HYDROCODONE USING A SUPER ACID 审中-公开
    使用超酸制备氢醌的方法

    公开(公告)号:WO2010065441A1

    公开(公告)日:2010-06-10

    申请号:PCT/US2009/066067

    申请日:2009-11-30

    CPC classification number: C07D489/02 C07D221/28

    Abstract: The present disclosure generally relates to a process for converting a fused, tricyclic compound to a fused, tetracyclic compound that includes a furan ring therein. More particularly, the present disclosure related to a process for preparing a hydrocodone compound, or a compound structurally related thereto, and in particular (+)-hydrocodone, by subjecting a structurally corresponding sinomeπine starting compound to a super acid-assisted furan ring closure reaction. Formula I, II. Examples of super acids useful in the processes described herein include, but are not limited to, trifluoromethanesulfonic acid (CF 3 SO 3 H), tetrafluoroboric acid (HBF 4 ), fluorophosphoric acid (HPF 6 ), fluorosulfuric acid (FSO 3 H). and fiuoroantimonic acid (HSbF 8 ), fluorophosphoric acid (FP(O)(OH) 2 ) as well as combinations thereof.

    Abstract translation: 本公开内容一般涉及将稠合的三环化合物转化为在其中包含呋喃环的稠合四环化合物的方法。 更具体地,本公开涉及制备氢可酮化合物或其结构相关的化合物的方法,特别是(+) - 氢可酮,通过使结构上相应的脯氨酸起始化合物经受超酸辅助的呋喃环闭合反应 。 公式I,II。 可用于本文所述方法的超级酸的实例包括但不限于三氟甲磺酸(CF 3 SO 3 H),四氟硼酸(HBF 4),氟代磷酸(HPF 6),氟代硫酸(FSO 3 H)。 和氟代苹果酸(HSbF8),氟磷酸(FP(O)(OH)2))以及它们的组合。

    OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF
    10.
    发明申请
    OPIOID AND OPIOID-LIKE COMPOUNDS AND USES THEREOF 审中-公开
    OPIOID和类似阿片类似物的化合物及其用途

    公开(公告)号:WO2003097608A2

    公开(公告)日:2003-11-27

    申请号:PCT/US2003/015461

    申请日:2003-05-16

    CPC classification number: A61K31/485

    Abstract: The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations containing the same and methods of use thereof. Uses of the present invention include, but are not limited to, use for the prevention and treatment of septic shock and other disorders. The compounds described herein can be water soluble and can act through mechanisms mediated through pathways other than opiate receptors.

    Abstract translation: 本发明涉及阿片样物质和阿片样物质化合物,以及含有其的药物制剂及其使用方法。 本发明的用途包括但不限于用于预防和治疗败血性休克和其它疾病的用途。 本文所述的化合物可以是水溶性的,并且可以通过除阿片受体之外的途径介导的机制起作用。

Patent Agency Ranking